Last reviewed · How we verify
FOLFOX or CAPOX adjuvant chemotherapy
FOLFOX and CAPOX are combination chemotherapy regimens that use fluorouracil and oxaliplatin to damage cancer cell DNA and inhibit cell division.
FOLFOX and CAPOX are combination chemotherapy regimens that use fluorouracil and oxaliplatin to damage cancer cell DNA and inhibit cell division. Used for Adjuvant treatment of stage III colon cancer, Adjuvant treatment of stage II colon cancer (high-risk features).
At a glance
| Generic name | FOLFOX or CAPOX adjuvant chemotherapy |
|---|---|
| Sponsor | Seoul National University Hospital |
| Drug class | Platinum-based combination chemotherapy |
| Target | DNA (oxaliplatin crosslinking); thymidylate synthase (fluoropyrimidines) |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | Phase 3 |
Mechanism of action
FOLFOX combines 5-fluorouracil (5-FU), leucovorin, and oxaliplatin; CAPOX substitutes capecitabine for infusional 5-FU. Oxaliplatin is a platinum agent that forms DNA crosslinks, while fluoropyrimidines inhibit thymidylate synthase and incorporate into DNA/RNA. Together they create synergistic cytotoxic effects against rapidly dividing cancer cells.
Approved indications
- Adjuvant treatment of stage III colon cancer
- Adjuvant treatment of stage II colon cancer (high-risk features)
Common side effects
- Neuropathy (peripheral sensory)
- Nausea and vomiting
- Diarrhea
- Neutropenia
- Fatigue
- Anemia
- Thrombocytopenia
Key clinical trials
- Perioperative Systemic Therapy for Isolated Resectable Colorectal Peritoneal Metastases (PHASE2, PHASE3)
- Neoadjuvant Chemotherapy for Obstructive Colon cancER First Treated by cOlostomy (PHASE3)
- SMART TNT for the Conservative Management of Locally Advanced Rectal Cancer (PHASE1)
- Personalizing Chemotherapy Selection After Surgery for Patients With Stage III Colorectal Cancer Using a Blood Test (PHASE3)
- ctDNA-Based Adjuvant Chemotherapy for High-Risk Rectal Cancer (PHASE3)
- SBRT of Metastases Following Neo-adjuvant Treatment for Colorectal Cancer With Synchronous Liver Metastases (PHASE2)
- Dose Individualization of Chemotherapy in Patients With Gastrointestinal Cancers Lacking a Specific Liver Enzyme (PHASE2)
- Platform Study of Circulating Tumor DNA Directed Adjuvant Chemotherapy in Colon Cancer (KCSG CO22-12) (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: